| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | pantothenate kinase activity | 3.59e-06 | 4 | 194 | 3 | GO:0004594 | |
| GeneOntologyMolecularFunction | growth factor receptor binding | 5.04e-05 | 173 | 194 | 9 | GO:0070851 | |
| GeneOntologyMolecularFunction | CTP synthase activity | 9.39e-05 | 2 | 194 | 2 | GO:0003883 | |
| GeneOntologyMolecularFunction | ATP-dependent activity | MYH6 ABCA1 MYO6 NAIP CHD3 CHD4 KIF2B NAV3 HFM1 HSP90AB1 FIGNL2 SMC4 ATP2C1 ABCA6 DYNC1LI1 MACF1 HSP90AB2P | 1.09e-04 | 614 | 194 | 17 | GO:0140657 |
| GeneOntologyMolecularFunction | ATP hydrolysis activity | ABCA1 NAIP CHD3 CHD4 KIF2B NAV3 HFM1 HSP90AB1 FIGNL2 SMC4 ATP2C1 ABCA6 MACF1 HSP90AB2P | 1.10e-04 | 441 | 194 | 14 | GO:0016887 |
| GeneOntologyCellularComponent | anchoring junction | KLHL24 PSG6 PSG9 ITGB1BP1 TRPC6 SRP68 ITGA4 ADAM17 EVL NRAP DSG3 DSP EPB41L5 TEC CBL KRIT1 AFAP1 IGF2R HMCN1 IL1RL1 CTNNA2 CGNL1 OCLN | 3.94e-05 | 976 | 194 | 23 | GO:0070161 |
| GeneOntologyCellularComponent | basal plasma membrane | ABCA1 PSG6 PSG9 NAIP AP2A1 PTPRQ HSP90AB1 DSP SLC7A7 LEPR SLCO5A1 CTNNA2 | 1.23e-04 | 354 | 194 | 12 | GO:0009925 |
| GeneOntologyCellularComponent | cell-cell junction | KLHL24 PSG6 PSG9 TRPC6 ITGA4 ADAM17 NRAP DSG3 DSP EPB41L5 TEC KRIT1 HMCN1 CTNNA2 CGNL1 OCLN | 1.34e-04 | 591 | 194 | 16 | GO:0005911 |
| GeneOntologyCellularComponent | basolateral plasma membrane | ABCA1 PSG6 PSG9 NAIP AP2A1 HSP90AB1 DSP SLC7A7 LEPR SLCO5A1 CTNNA2 | 2.09e-04 | 320 | 194 | 11 | GO:0016323 |
| GeneOntologyCellularComponent | basal part of cell | ABCA1 PSG6 PSG9 NAIP AP2A1 PTPRQ HSP90AB1 DSP SLC7A7 LEPR SLCO5A1 CTNNA2 | 2.26e-04 | 378 | 194 | 12 | GO:0045178 |
| GeneOntologyCellularComponent | cytoophidium | 2.55e-04 | 3 | 194 | 2 | GO:0097268 | |
| Domain | Type_II_PanK | 4.05e-06 | 4 | 189 | 3 | IPR004567 | |
| Domain | Fumble | 4.05e-06 | 4 | 189 | 3 | PF03630 | |
| Domain | CTP_synthase_N | 1.02e-04 | 2 | 189 | 2 | IPR017456 | |
| Domain | GATase1_CTP_Synthase | 1.02e-04 | 2 | 189 | 2 | IPR033828 | |
| Domain | CTP_synthase | 1.02e-04 | 2 | 189 | 2 | IPR004468 | |
| Domain | CTP_synth_N | 1.02e-04 | 2 | 189 | 2 | PF06418 | |
| Domain | CHD_N | 3.04e-04 | 3 | 189 | 2 | IPR012958 | |
| Domain | CHD_C2 | 3.04e-04 | 3 | 189 | 2 | IPR012957 | |
| Domain | CHDCT2 | 3.04e-04 | 3 | 189 | 2 | PF08074 | |
| Domain | CHDNT | 3.04e-04 | 3 | 189 | 2 | PF08073 | |
| Domain | DUF1086 | 3.04e-04 | 3 | 189 | 2 | IPR009462 | |
| Domain | DUF1087 | 3.04e-04 | 3 | 189 | 2 | IPR009463 | |
| Domain | DUF1087 | 3.04e-04 | 3 | 189 | 2 | PF06465 | |
| Domain | DUF1086 | 3.04e-04 | 3 | 189 | 2 | PF06461 | |
| Domain | DUF1087 | 3.04e-04 | 3 | 189 | 2 | SM01147 | |
| Domain | DUF1086 | 3.04e-04 | 3 | 189 | 2 | SM01146 | |
| Pathway | REACTOME_COENZYME_A_BIOSYNTHESIS | 3.26e-05 | 7 | 140 | 3 | M27087 | |
| Pathway | REACTOME_COENZYME_A_BIOSYNTHESIS | 3.26e-05 | 7 | 140 | 3 | MM14765 | |
| Pubmed | SERBP1 MYO6 SRP68 PSMD3 DDB1 PARP1 HSP90AB1 KPNA2 DSP ICE2 CIP2A SMC4 EPB41L5 ARHGAP39 ERLIN1 FAM83B IGF2R MACF1 OCLN PLCH1 CTPS1 CNOT1 | 1.27e-10 | 708 | 197 | 22 | 39231216 | |
| Pubmed | MYH6 CENPC PSMD3 CHD3 CHD4 PARP1 AP2A1 SACS TMPRSS7 USP1 KIAA2012 AGAP2 HSP90AB1 EVL ABI3BP PCDHGB2 KDM5A PCDHGB1 DSP SMC4 APOB RNF17 ERLIN1 SUGCT C4orf51 OGDHL DNAJC5 MACF1 MYOM2 PLCH1 | 7.91e-10 | 1442 | 197 | 30 | 35575683 | |
| Pubmed | MYH6 SERBP1 MYO6 SRP68 PSMD3 CHD3 DDB1 MRPS22 PARP1 AP2A1 SACS PLP1 AGAP2 HSP90AB1 EVL DSP GRIN2B ARHGAP39 LDHB GDA AFAP1 PDE4DIP OGDHL MACF1 CTNNA2 CGNL1 PLCH1 CNOT1 | 1.16e-08 | 1431 | 197 | 28 | 37142655 | |
| Pubmed | Direct interaction between hnRNP-M and CDC5L/PLRG1 proteins affects alternative splice site choice. | ORC6 SRP68 PSMD3 CHD3 CHD4 DDB1 PARP1 XPO6 HSP90AB1 KPNA2 DSP POLD1 SMC4 RNF17 DYNC1LI1 MACF1 CNOT1 | 4.37e-08 | 582 | 197 | 17 | 20467437 |
| Pubmed | SERBP1 MYO6 ORC6 PSMD3 CHD4 ITGA4 LMBRD2 PARP1 AP2A1 PIK3CG GLG1 ADAM17 AGAP2 HSP90AB1 KPNA2 EVL POLD1 LDHB ATP2C1 IGF2R DYNC1LI1 DNAJC5 CTPS1 CNOT1 | 5.78e-08 | 1168 | 197 | 24 | 19946888 | |
| Pubmed | MYO6 DOCK11 SRP68 PSMD3 CHD4 DDB1 PARP1 DOCK6 HSP90AB1 DSP POLR2B SMC4 LDHB CTPS1 | 7.74e-08 | 399 | 197 | 14 | 37536630 | |
| Pubmed | MYO6 TTC14 SACS ELAPOR1 CIP2A EPB41L5 ARHGAP39 FAN1 GDA ATP2C1 CNTNAP4 MACF1 CGNL1 PLCH1 TMEM63A | 1.66e-07 | 493 | 197 | 15 | 15368895 | |
| Pubmed | 1.79e-07 | 3 | 197 | 3 | 17631502 | ||
| Pubmed | 1.79e-07 | 3 | 197 | 3 | 23152917 | ||
| Pubmed | 1.79e-07 | 3 | 197 | 3 | 17379144 | ||
| Pubmed | CDK16 SERBP1 SRP68 PSMD3 CHD3 CHD4 EFHB DDB1 MRPS22 PARP1 AP2A1 HSP90AB1 KPNA2 WASHC4 KDM5A DSP SMC4 LDHB IGF2R ZCRB1 DYNC1LI1 MACF1 HSP90AB2P | 1.88e-07 | 1153 | 197 | 23 | 29845934 | |
| Pubmed | Targeting USP10 induces degradation of oncogenic ANLN in esophageal squamous cell carcinoma. | SERBP1 SAMD9 MYO6 SRP68 PSMD3 ITGA4 DDB1 MRPS22 ITIH2 DECR1 PARP1 AP2A1 HSP90AB1 KPNA2 DSG3 DSP POLR2B SMC4 LDHB ERLIN1 FAM83B AFAP1 CSTA CTPS1 | 2.22e-07 | 1257 | 197 | 24 | 36526897 |
| Pubmed | TDRD15 MYH6 SERBP1 SRP68 PSMD3 CHD3 MAP3K1 AP2A1 HSP90AB1 KPNA2 DSP LDHB GDA HMCN1 CSTA MACF1 HSP90AB2P CTNNA2 CTPS1 | 3.91e-07 | 844 | 197 | 19 | 25963833 | |
| Pubmed | A central chaperone-like role for 14-3-3 proteins in human cells. | CDK16 DOCK11 FSIP2 BMX PANK2 DOCK6 PANK3 KDM5A DSP EPB41L5 RAB11FIP1 CBL FAM83B SLF2 MACF1 PLEKHM3 CGNL1 PLCH1 EDRF1 | 5.28e-07 | 861 | 197 | 19 | 36931259 |
| Pubmed | Tumor suppressor BAP1 nuclear import is governed by transportin-1. | SERBP1 MYO6 SRP68 PSMD3 CHD4 DDB1 MRPS22 PARP1 AP2A1 HSP90AB1 KPNA2 PSAT1 DSP POLD1 CIP2A POLR2B SMC4 LDHB DYNC1LI1 MACF1 CTPS1 CNOT1 | 7.02e-07 | 1149 | 197 | 22 | 35446349 |
| Pubmed | 7.13e-07 | 4 | 197 | 3 | 22815849 | ||
| Pubmed | 7.13e-07 | 4 | 197 | 3 | 2981478 | ||
| Pubmed | A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. | 7.13e-07 | 4 | 197 | 3 | 11479594 | |
| Pubmed | CDK16 PSEN1 MYO6 SRP68 MRPS22 PARP1 AP2A1 NUAK1 EVL CIP2A ERLIN1 FAM83B ATP2C1 IGF2R MACF1 CTNNA2 | 7.73e-07 | 634 | 197 | 16 | 34591612 | |
| Pubmed | Proteomic profiling of VCP substrates links VCP to K6-linked ubiquitylation and c-Myc function. | CENPC MYO6 SRP68 PSMD3 CHD4 DDB1 DECR1 PARP1 AP2A1 HSP90AB1 WASHC4 DSP POLD1 POLR2B SMC4 EPB41L5 LDHB ERLIN1 PRIM2 CSTA DYNC1LI1 MACF1 HSP90AB2P CTPS1 | 8.23e-07 | 1353 | 197 | 24 | 29467282 |
| Pubmed | USP11 mediates repair of DNA-protein cross-links by deubiquitinating SPRTN metalloprotease. | SERBP1 MYO6 PSMD3 DDB1 PARP1 CTPS2 GMDS HSP90AB1 KPNA2 LDHB ERLIN1 ATP2C1 DYNC1LI1 HSP90AB2P CTPS1 | 9.27e-07 | 565 | 197 | 15 | 33567341 |
| Pubmed | CDK16 ITGA4 RGP1 CTPS2 AP2A1 EPB41L5 RAB11FIP1 CBL FAM83B IGF2R MACF1 OCLN PLCH1 | 9.63e-07 | 421 | 197 | 13 | 36976175 | |
| Pubmed | 1.01e-06 | 234 | 197 | 10 | 36243803 | ||
| Pubmed | MECP2 directly interacts with RNA polymerase II to modulate transcription in human neurons. | SRP68 CHD4 DDB1 MRPS22 PARP1 AP2A1 SACS DOCK6 HSP90AB1 KPNA2 SUPT20H KDM5A DSP POLR2B ARHGAP39 LDHB AFAP1 IRAK4 DYNC1LI1 MACF1 CNOT1 | 1.03e-06 | 1082 | 197 | 21 | 38697112 |
| Pubmed | USP34 MYO6 CHD4 BICD1 PARP1 PTPRD AP2A1 SACS NAV3 PLP1 AGAP2 HSP90AB1 SUPT20H WASHC4 KDM5A DSP GRIN2B KRIT1 FAN1 GMCL1 SLF2 PDE4DIP MACF1 | 1.22e-06 | 1285 | 197 | 23 | 35914814 | |
| Pubmed | USP34 SERBP1 PSEN1 ITIH2 FAT4 ARHGAP39 AFAP1 DYNC1LI1 CTNNA2 PLCH1 | 1.58e-06 | 246 | 197 | 10 | 15345747 | |
| Pubmed | SERBP1 SRP68 PSMD3 CHD4 PARP1 KPNA2 FAT4 DSP POLR2B SMC4 APOB RAB11FIP1 RNF17 TSPAN3 SETDB2 ATP2C1 CTPS1 | 1.61e-06 | 754 | 197 | 17 | 35906200 | |
| Pubmed | Assembly of the U5 snRNP component PRPF8 is controlled by the HSP90/R2TP chaperones. | SERBP1 SRP68 PSMD3 CHD4 DDB1 MRPS22 DECR1 PARP1 CTPS2 AP2A1 GLG1 GMDS HSP90AB1 KPNA2 DSP POLD1 POLR2B SMC4 LDHB GDA PRIM2 MACF1 HSP90AB2P CTPS1 | 1.80e-06 | 1415 | 197 | 24 | 28515276 |
| Pubmed | Gain of Additional BIRC3 Protein Functions through 3'-UTR-Mediated Protein Complex Formation. | SERBP1 MYO6 RGS22 SRP68 PSMD3 CHD4 DDB1 PARP1 AP2A1 HSP90AB1 KPNA2 PSAT1 DSP POLD1 POLR2B SMC4 APOB LDHB GLMN IGF2R CSTA DYNC1LI1 CTPS1 CNOT1 | 2.03e-06 | 1425 | 197 | 24 | 30948266 |
| Pubmed | USP34 SERBP1 PSMD3 CHD4 LMBRD2 DDB1 MRPS22 DECR1 PARP1 KPNA2 PSAT1 POLD1 CIP2A POLR2B SMC4 ERLIN1 GLMN AFAP1 CSTA DYNC1LI1 HSP90AB2P CTNNA2 CTPS1 CNOT1 | 2.43e-06 | 1440 | 197 | 24 | 30833792 | |
| Pubmed | ISG15 Connects Autophagy and IFN-γ-Dependent Control of Toxoplasma gondii Infection in Human Cells. | SERBP1 MYO6 PSMD3 DDB1 PARP1 AP2A1 HSP90AB1 KPNA2 LDHB ERLIN1 | 3.40e-06 | 268 | 197 | 10 | 33024031 |
| Pubmed | A BioID-Derived Proximity Interactome for SARS-CoV-2 Proteins. | SLC38A9 LMBRD2 MRPS22 XPO6 ADAM17 NEMP1 CIP2A EPB41L5 ARHGAP39 RAB11FIP1 SLC7A7 TSPAN3 IGF2R PRIM2 DNAJC5 MACF1 | 3.89e-06 | 719 | 197 | 16 | 35337019 |
| Pubmed | SRP68 PSMD3 CHD4 DDB1 PARP1 HSP90AB1 KPNA2 POLD1 CIP2A POLR2B SMC4 PRIM2 DYNC1LI1 CTPS1 CNOT1 | 4.09e-06 | 638 | 197 | 15 | 33239621 | |
| Pubmed | SRP68 PARP1 AP2A1 GLG1 HSP90AB1 KPNA2 DSP POLR2B SMC4 APOB RAB11FIP1 ERLIN1 TMEM106B GLMN GDA AFAP1 IGF2R CSTA MACF1 CTNNA2 CTPS1 CNOT1 | 4.99e-06 | 1297 | 197 | 22 | 33545068 | |
| Pubmed | NAIP ADCY5 AP2A1 SACS AGAP2 HSP90AB1 GRIN2B ARHGAP39 DNAJC5 MACF1 CTNNA2 | 5.23e-06 | 347 | 197 | 11 | 17114649 | |
| Pubmed | HAPSTR1 localizes HUWE1 to the nucleus to limit stress signaling pathways. | USP34 SRP68 PSMD3 DDB1 MRPS22 GMDS HSP90AB1 CIP2A POLR2B LDHB TMEM106B IGF2R DYNC1LI1 CTPS1 | 5.38e-06 | 571 | 197 | 14 | 37167062 |
| Pubmed | ITGB1BP1 SRP68 CHD4 PRKD3 USP1 HSP90AB1 NRAP KDM5A DSP BRMS1L PDE4DIP MACF1 MYOM2 | 5.90e-06 | 497 | 197 | 13 | 23414517 | |
| Pubmed | 6.16e-06 | 7 | 197 | 3 | 9563011 | ||
| Pubmed | LMBR1L regulates lymphopoiesis through Wnt/β-catenin signaling. | MYO6 SRP68 CTPS2 AP2A1 XPO6 HSP90AB1 KPNA2 NEMP1 CIP2A POLR2B SMC4 TSPAN3 ERLIN1 GLMN ATP2C1 IGF2R DYNC1LI1 OCLN | 7.83e-06 | 942 | 197 | 18 | 31073040 |
| Pubmed | USP34 SERBP1 MYO6 SRP68 PSMD3 CHST9 CHD3 CHD4 DDB1 MRPS22 PARP1 CTPS2 AP2A1 HSP90AB1 KPNA2 WASHC4 ICE2 POLR2B LDHB PRIM2 HSP90AB2P CTPS1 | 7.85e-06 | 1335 | 197 | 22 | 29229926 | |
| Pubmed | CENPC PSMD3 PARP1 PTPRD USP1 HSP90AB1 KPNA2 PSAT1 DSP CIP2A POLR2B ARHGAP39 RAB11FIP1 PTPRT FAN1 GLMN IGF2R PRIM2 CNOT1 | 9.23e-06 | 1049 | 197 | 19 | 27880917 | |
| Pubmed | 1.04e-05 | 131 | 197 | 7 | 35356984 | ||
| Pubmed | DOCK11 CHD4 DDB1 PARP1 PTPRD AP2A1 PLP1 AGAP2 HSP90AB1 KDM5A GRIN2B ARHGAP39 GDA IGF2R PDE4DIP MACF1 CTNNA2 CNOT1 | 1.05e-05 | 963 | 197 | 18 | 28671696 | |
| Pubmed | Epidermal development requires ninein for spindle orientation and cortical microtubule organization. | 1.35e-05 | 26 | 197 | 4 | 30923192 | |
| Pubmed | SERBP1 PSMD3 CHD3 STAT2 DECR1 PARP1 HSP90AB1 PSAT1 POLR2B SMC4 LDHB MACF1 HSP90AB2P | 1.37e-05 | 538 | 197 | 13 | 28524877 | |
| Pubmed | The STUbL RNF4 regulates protein group SUMOylation by targeting the SUMO conjugation machinery. | USP34 ZNF765 CENPC PSMD3 CHD4 PARP1 AP2A1 GLG1 ADAM17 HSP90AB1 WASHC4 DSP CIP2A CBL ERLIN1 TMEM106B ATP2C1 IGF2R OCLN CNOT1 | 1.84e-05 | 1203 | 197 | 20 | 29180619 |
| Pubmed | PSMD3 PARP1 GLG1 HSP90AB1 KPNA2 PSAT1 DSP SMC4 LDHB CSTA CTPS1 | 1.84e-05 | 397 | 197 | 11 | 21319273 | |
| Pubmed | PINK1 Content in Mitochondria is Regulated by ER-Associated Degradation. | MYO6 SRP68 PSMD3 CHD4 PARP1 HSP90AB1 PSAT1 DSP SMC4 LDHB CSTA CTPS1 | 1.99e-05 | 477 | 197 | 12 | 31300519 |
| Pubmed | MYO6 PSMD3 DDB1 AP2A1 GLG1 HSP90AB1 POLR2B SMC4 GLMN DYNC1LI1 OCLN CTPS1 CNOT1 | 2.08e-05 | 560 | 197 | 13 | 35241646 | |
| Pubmed | 2.09e-05 | 10 | 197 | 3 | 15210844 | ||
| Pubmed | Common variants near ABCA1, AFAP1 and GMDS confer risk of primary open-angle glaucoma. | 2.09e-05 | 10 | 197 | 3 | 25173105 | |
| Pubmed | USP34 SRP68 DDB1 STAT2 USP1 ICE2 CIP2A POLR2B EPB41L5 GLMN IGF2R DYNC1LI1 DNAJC5 PLCH1 CTPS1 | 2.10e-05 | 733 | 197 | 15 | 34672954 | |
| Pubmed | Mapping the NPHP-JBTS-MKS protein network reveals ciliopathy disease genes and pathways. | PSMD3 CHD4 DDB1 NAV3 HSP90AB1 DSP POLR2B EPB41L5 LDHB IGF2R GUCY2C PRIM2 TMEM63A | 2.24e-05 | 564 | 197 | 13 | 21565611 |
| Pubmed | 2.65e-05 | 208 | 197 | 8 | 22145905 | ||
| Pubmed | SRP68 PSMD3 DDB1 PARP1 HSP90AB1 KPNA2 DSP LRRK1 LDHB HSP90AB2P CTPS1 CNOT1 | 2.80e-05 | 494 | 197 | 12 | 26831064 | |
| Pubmed | Lis1 is essential for cortical microtubule organization and desmosome stability in the epidermis. | 2.86e-05 | 11 | 197 | 3 | 21844209 | |
| Pubmed | Two-Dimensional Fractionation Method for Proteome-Wide Cross-Linking Mass Spectrometry Analysis. | SERBP1 MYO6 PSMD3 CHD3 CHD4 MRPS22 PARP1 HSP90AB1 DSP SMC4 LDHB ERLIN1 DYNC1LI1 DNAJC5 MACF1 HSP90AB2P | 2.92e-05 | 847 | 197 | 16 | 35235311 |
| Pubmed | A high-throughput approach for measuring temporal changes in the interactome. | USP34 SERBP1 SRP68 PSMD3 DDB1 CTPS2 GMDS HSP90AB1 KPNA2 PSAT1 WASHC4 POLD1 POLR2B SMC4 LDHB GDA PRIM2 DYNC1LI1 MACF1 HSP90AB2P CTPS1 CNOT1 | 2.93e-05 | 1455 | 197 | 22 | 22863883 |
| Pubmed | The E3 ubiquitin ligase HECTD1 contributes to cell proliferation through an effect on mitosis. | SERBP1 SRP68 PSMD3 CHD3 CHD4 DDB1 MRPS22 MAP3K1 DECR1 AP2A1 KPNA2 POLR2B OGDHL MACF1 CNOT1 | 3.13e-05 | 759 | 197 | 15 | 35915203 |
| Pubmed | 3.17e-05 | 32 | 197 | 4 | 23049088 | ||
| Pubmed | The human cytoplasmic dynein interactome reveals novel activators of motility. | SERBP1 PKD1L1 DDB1 BICD1 DECR1 HSP90AB1 DSP CIP2A POLR2B ERLIN1 FAM83B GLMN IGF2R DYNC1LI1 CGNL1 CNOT1 | 3.18e-05 | 853 | 197 | 16 | 28718761 |
| Pubmed | 3.19e-05 | 2 | 197 | 2 | 11741838 | ||
| Pubmed | 3.19e-05 | 2 | 197 | 2 | 28694219 | ||
| Pubmed | 3.19e-05 | 2 | 197 | 2 | 7575689 | ||
| Pubmed | 3.19e-05 | 2 | 197 | 2 | 26565020 | ||
| Pubmed | 3.19e-05 | 2 | 197 | 2 | 22543864 | ||
| Pubmed | 3.19e-05 | 2 | 197 | 2 | 32487715 | ||
| Pubmed | 3.19e-05 | 2 | 197 | 2 | 31270351 | ||
| Pubmed | 3.19e-05 | 2 | 197 | 2 | 18794297 | ||
| Pubmed | Two distinct GUCY2C circuits with PMV (hypothalamic) and SN/VTA (midbrain) origin. | 3.19e-05 | 2 | 197 | 2 | 31485718 | |
| Pubmed | 3.19e-05 | 2 | 197 | 2 | 20392263 | ||
| Pubmed | 3.19e-05 | 2 | 197 | 2 | 18412156 | ||
| Pubmed | USP1 inhibition destabilizes KPNA2 and suppresses breast cancer metastasis. | 3.19e-05 | 2 | 197 | 2 | 30531833 | |
| Pubmed | Feedback regulation of murine pantothenate kinase 3 by coenzyme A and coenzyme A thioesters. | 3.19e-05 | 2 | 197 | 2 | 16040613 | |
| Pubmed | A therapeutic approach to pantothenate kinase associated neurodegeneration. | 3.19e-05 | 2 | 197 | 2 | 30352999 | |
| Pubmed | Cocrystal structure of the ICAP1 PTB domain in complex with a KRIT1 peptide. | 3.19e-05 | 2 | 197 | 2 | 23695561 | |
| Pubmed | Mouse Chd4-NURD is required for neonatal spermatogonia survival and normal gonad development. | 3.19e-05 | 2 | 197 | 2 | 35568926 | |
| Pubmed | Regulation of human cytidine triphosphate synthetase 2 by phosphorylation. | 3.19e-05 | 2 | 197 | 2 | 20739275 | |
| Pubmed | Molecular analysis of a major antigenic region of the 240-kD protein of Mi-2 autoantigen. | 3.19e-05 | 2 | 197 | 2 | 7560064 | |
| Pubmed | CIP2A-promoted astrogliosis induces AD-like synaptic degeneration and cognitive deficits. | 3.19e-05 | 2 | 197 | 2 | 30594047 | |
| Pubmed | 3.19e-05 | 2 | 197 | 2 | 24025330 | ||
| Pubmed | 3.19e-05 | 2 | 197 | 2 | 24637679 | ||
| Pubmed | 3.19e-05 | 2 | 197 | 2 | 28963139 | ||
| Pubmed | 3.19e-05 | 2 | 197 | 2 | 33070372 | ||
| Pubmed | 3.19e-05 | 2 | 197 | 2 | 20807704 | ||
| Pubmed | 3.19e-05 | 2 | 197 | 2 | 27026705 | ||
| Pubmed | 3.19e-05 | 2 | 197 | 2 | 28904022 | ||
| Pubmed | 3.19e-05 | 2 | 197 | 2 | 30076206 | ||
| Pubmed | 3.19e-05 | 2 | 197 | 2 | 21698215 | ||
| Pubmed | 3.19e-05 | 2 | 197 | 2 | 11854171 | ||
| Pubmed | 3.19e-05 | 2 | 197 | 2 | 37821462 | ||
| Pubmed | Exome sequencing: an efficient diagnostic tool for complex neurodegenerative disorders. | 3.19e-05 | 2 | 197 | 2 | 23043354 | |
| Pubmed | 3.19e-05 | 2 | 197 | 2 | 16227264 | ||
| Pubmed | Long single alpha-helical tail domains bridge the gap between structure and function of myosin VI. | 3.19e-05 | 2 | 197 | 2 | 18511944 | |
| Pubmed | Prevalence of ANGPTL3 and APOB gene mutations in subjects with combined hypolipidemia. | 3.19e-05 | 2 | 197 | 2 | 22247256 | |
| Pubmed | Two forms of the major antigenic protein of the dermatomyositis-specific Mi-2 autoantigen. | 3.19e-05 | 2 | 197 | 2 | 8843877 | |
| Pubmed | 3.19e-05 | 2 | 197 | 2 | 18535744 | ||
| Pubmed | Krit1 modulates beta 1-integrin-mediated endothelial cell proliferation. | 3.19e-05 | 2 | 197 | 2 | 18812969 | |
| Pubmed | BLOC1S1 RGP1 BICD1 PRKD3 ADAM17 DOCK6 WASHC4 FAM83B TMEM106B IGF2R PLEKHM3 OCLN | 3.40e-05 | 504 | 197 | 12 | 34432599 | |
| Pubmed | C9orf72 protein quality control by UBR5-mediated heterotypic ubiquitin chains. | SERBP1 MYO6 PSMD3 DDB1 PARP1 CTPS2 GMDS USP1 HSP90AB1 KPNA2 DSP POLD1 POLR2B SMC4 LDHB ERLIN1 DYNC1LI1 HSP90AB2P CTPS1 CNOT1 | 3.41e-05 | 1257 | 197 | 20 | 37317656 |
| Interaction | JUP interactions | SERBP1 PSEN1 MYO6 CHD3 CHD4 PARP1 PTPRQ USP1 HSP90AB1 PSAT1 DSG3 DSP GMCL1 PDE4DIP CSTA DNAJC5 CTNNA2 OCLN | 9.78e-07 | 485 | 192 | 18 | int:JUP |
| Interaction | PRKACA interactions | CDK16 ABCA1 PSEN1 ITGA4 ADCY5 NUAK1 AGAP2 HSP90AB1 EVL DSP SI GRIN2B CBL FAM83B IGF2R PDE4DIP DNAJC5 OCLN | 2.55e-06 | 519 | 192 | 18 | int:PRKACA |
| Interaction | MCM2 interactions | TDRD15 MYH6 SERBP1 ORC6 SRP68 PSMD3 CHD3 CHD4 ITGA4 MAP3K1 PARP1 AP2A1 NUAK1 HSP90AB1 KPNA2 DSP SMC4 LDHB GDA HMCN1 CSTA MACF1 HSP90AB2P CTNNA2 CTPS1 CNOT1 | 1.29e-05 | 1081 | 192 | 26 | int:MCM2 |
| Interaction | EED interactions | CENPC MYO6 AS3MT SRP68 PSMD3 CHD3 CHD4 ITGA4 DDB1 PARP1 AP2A1 ADAM17 HSP90AB1 KPNA2 PSAT1 WASHC4 KDM5A DSP POLD1 CIP2A POLR2B SMC4 BRMS1L CBL GLMN IGF2R RMDN1 MACF1 CGNL1 CTPS1 CNOT1 | 1.72e-05 | 1445 | 192 | 31 | int:EED |
| Interaction | LAMTOR1 interactions | CDK16 PSEN1 MYO6 SLC38A9 BLOC1S1 LMBRD2 PRKD3 PTPRD AP2A1 EPB41L5 RAB11FIP1 FAM83B TMEM106B ATP2C1 IGF2R DNAJC5 PLEKHM3 OCLN PLCH1 EDRF1 | 1.97e-05 | 722 | 192 | 20 | int:LAMTOR1 |
| Interaction | KCNA3 interactions | SERBP1 MYO6 SRP68 PSMD3 DDB1 PARP1 HSP90AB1 KPNA2 DSP ICE2 CIP2A SMC4 EPB41L5 ARHGAP39 ERLIN1 FAM83B IGF2R MACF1 OCLN PLCH1 CTPS1 CNOT1 | 3.06e-05 | 871 | 192 | 22 | int:KCNA3 |
| GeneFamily | Protein tyrosine phosphatases, receptor type | 4.30e-04 | 21 | 129 | 3 | 813 | |
| GeneFamily | Pleckstrin homology domain containing|Rho guanine nucleotide exchange factors|C2 domain containing | 6.97e-04 | 206 | 129 | 7 | 682 | |
| ToppCell | facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-thymocyte|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | RGS22 PTPRD PTPRQ NAV3 FAT4 FAT3 APOB GRIN2B HMCN1 CCBE1 CNTNAP4 MYOM2 PLCH1 | 2.05e-12 | 184 | 196 | 13 | 2cbed6462fea2622871bb7e49b0df3d984239281 |
| ToppCell | facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-proliferating_thymocyte;_DN_to_DP_transition,_dividing_(some_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination)|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | RGS22 PTPRD PTPRQ NAV3 FAT4 FAT3 APOB GRIN2B HMCN1 CCBE1 CNTNAP4 MYOM2 PLCH1 | 2.05e-12 | 184 | 196 | 13 | 2b19a8c5f823e00812908b23e66bb4e563278aff |
| ToppCell | facs-Thymus-Thymus_Epithelium-18m-Lymphocytic|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | RGS22 PTPRD PTPRQ NAV3 FAT4 FAT3 APOB GRIN2B HMCN1 CCBE1 CNTNAP4 MYOM2 PLCH1 | 2.05e-12 | 184 | 196 | 13 | ea7a7e2bac46d4d2c31a5d576b38a032b5335062 |
| ToppCell | TCGA-Pancreas-Primary_Tumor-Pancreatic_Adenocarcinoma-Ductal_Adenocarcinoma-4|TCGA-Pancreas / Sample_Type by Project: Shred V9 | ABCA1 DOCK11 RGS22 TLR7 ITGA4 PIK3CG NAV3 FAT4 ABI3BP LEPR HMCN1 ABCA6 | 3.77e-11 | 184 | 196 | 12 | 67164bb6bcae7322cb89b585c7aa10bce35b0ecd |
| ToppCell | droplet-Heart-HEART_(ALL_MINUS_AORTA)-30m-Endothelial-endocardial_endothelial_cells|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | BMX GMDS DOCK6 SMC4 RAB11FIP1 IGF2R HMCN1 CORIN CGNL1 OCLN CTPS1 TEC | 7.88e-11 | 196 | 196 | 12 | dbf154b3d166ffd07be717dac8d8a3350ac63e16 |
| ToppCell | droplet-Heart-nan-3m-Endothelial-endocardial_endothelial_cells|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | BMX NUAK1 DOCK6 SUPT20H SMC4 RAB11FIP1 IGF2R HMCN1 TXNRD3 CGNL1 OCLN | 8.44e-10 | 189 | 196 | 11 | fb2253b8463d08b3d28e952a31a23dea2c2d986b |
| ToppCell | droplet-Heart-HEART_(ALL_MINUS_AORTA)-30m-Endothelial-endocardial_cell|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | BMX GMDS DOCK6 SMC4 RAB11FIP1 IGF2R HMCN1 CORIN CGNL1 OCLN CTPS1 | 1.24e-09 | 196 | 196 | 11 | 7d5eaed189aa6116f3799be010139fb675ec65e0 |
| ToppCell | LPS_IL1RA_TNF-Mesenchymal_fibroblastic-Fibroblasts-Activated_MatrixFB|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type | PTPRD PXDNL EVL SELENOP ABI3BP POLD1 AFAP1 ABCA6 CCBE1 DYNC1LI1 MACF1 | 1.45e-09 | 199 | 196 | 11 | e1849505b92820a219c5a2c35492bdd55579fb48 |
| ToppCell | Control-Fibroblasts-Other_FB|Control / group, cell type (main and fine annotations) | 1.13e-08 | 187 | 196 | 10 | bd3739c4a52aa1ba5deffd778e113a9800f7e158 | |
| ToppCell | droplet-Heart-nan-3m-Endothelial-endocardial_cell|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | BMX NUAK1 DOCK6 SUPT20H SMC4 RAB11FIP1 HMCN1 TXNRD3 CGNL1 OCLN | 1.25e-08 | 189 | 196 | 10 | 8e583ec4df0f5b79ce5211cc99ecd8616d180bde |
| ToppCell | 5'-Adult-LargeIntestine-Epithelial-Tuft-related-Tuft|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | ARHGEF38 BMX PIK3CG ELAPOR1 GRIN2B PTPRT OGDHL CTNNA2 CGNL1 TMEM63A | 1.38e-08 | 191 | 196 | 10 | 54f07e4de61735051498846afb44b1798bed8144 |
| ToppCell | nucseq-Mesenchymal-Fibroblastic-Fibroblastic_2-AF1|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 1.38e-08 | 191 | 196 | 10 | 6688cee34beee4f151ac17fccbc9c26a9aad72e1 | |
| ToppCell | LPS_anti-TNF-Mesenchymal_fibroblastic-Fibroblasts-Activated_MatrixFB|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 1.86e-08 | 197 | 196 | 10 | fdb92985f7df0c280b87d3e43c2394e70786a2c7 | |
| ToppCell | Parenchymal-NucSeq-Stromal-Fibroblastic-Fibro_peribronchial|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 1.86e-08 | 197 | 196 | 10 | 44673c38384453207871d3fd8e8ba9093cc06bc5 | |
| ToppCell | 3'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2-Alveolar_fibroblasts-Alveolar_fibroblasts_L.2.1.1.1|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 1.86e-08 | 197 | 196 | 10 | 94a9603cbd3516fbcce871909693b88f20d41713 | |
| ToppCell | Tracheal-NucSeq-Stromal-Fibroblastic-Fibro_myofibroblast|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 1.86e-08 | 197 | 196 | 10 | 0dd71e399f253787fa546a7e90c5373180b89ffd | |
| ToppCell | LPS_IL1RA_TNF-Mesenchymal_fibroblastic-Fibroblasts-Diff_MatrixFB|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type | PTPRD PXDNL EVL SELENOP ABI3BP AFAP1 ABCA6 CCBE1 DYNC1LI1 MACF1 | 1.95e-08 | 198 | 196 | 10 | 0a4b19c3d5e65ecd24fc2ce80ac5276c813282c7 |
| ToppCell | LPS_IL1RA-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB|LPS_IL1RA / Treatment groups by lineage, cell group, cell type | 2.04e-08 | 199 | 196 | 10 | a7dd94b172c973a131a6792f8ccd9bfe44d984ac | |
| ToppCell | LPS_only-Mesenchymal_fibroblastic|LPS_only / Treatment groups by lineage, cell group, cell type | ABCA1 PXDNL EVL SELENOP ABI3BP POLD1 AFAP1 ABCA6 CCBE1 DYNC1LI1 | 2.04e-08 | 199 | 196 | 10 | 211c3a08f2d484ab7a3368006767289088f0d957 |
| ToppCell | LPS_IL1RA_TNF-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type | PTPRD NUAK1 PXDNL EVL SELENOP ABI3BP AFAP1 ABCA6 CCBE1 MACF1 | 2.04e-08 | 199 | 196 | 10 | 30d3e8c0681ec11f86dd38c5f48d21187a1b4f90 |
| ToppCell | LPS_only-Mesenchymal_fibroblastic-Fibroblasts|LPS_only / Treatment groups by lineage, cell group, cell type | ABCA1 PXDNL EVL SELENOP ABI3BP POLD1 AFAP1 ABCA6 CCBE1 DYNC1LI1 | 2.04e-08 | 199 | 196 | 10 | 1a0add79f4e34078b3475eb11c85a4234bda197c |
| ToppCell | LPS_only-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB|LPS_only / Treatment groups by lineage, cell group, cell type | ABCA1 PTPRD PXDNL EVL SELENOP ABI3BP ABCA6 CCBE1 DYNC1LI1 MACF1 | 2.14e-08 | 200 | 196 | 10 | a7ef7022b8efcaedb7319b0b43d8c4e99d788fe2 |
| ToppCell | Tracheal-NucSeq-Stromal-Fibroblastic-Fibro_peribronchial|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 2.14e-08 | 200 | 196 | 10 | 58b38f9a484ee94191091a0659ed62ebed2d4a14 | |
| ToppCell | LPS_anti-TNF-Mesenchymal_fibroblastic-Fibroblasts-Diff_MatrixFB|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | PTPRD PXDNL EVL SELENOP ABI3BP AFAP1 ABCA6 CCBE1 DYNC1LI1 MACF1 | 2.14e-08 | 200 | 196 | 10 | 3bdba9612cd7c612b76aa9abecc4a6529aabfc1c |
| ToppCell | LPS_IL1RA_TNF-Mesenchymal_fibroblastic-Fibroblasts|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type | PTPRD PXDNL EVL SELENOP ABI3BP AFAP1 ABCA6 CCBE1 DYNC1LI1 MACF1 | 2.14e-08 | 200 | 196 | 10 | 44a68bacdb3d5bf563bd35952176995850933a81 |
| ToppCell | Bronchial-NucSeq-Stromal-Fibroblastic|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 2.14e-08 | 200 | 196 | 10 | cae972324d1dfea6efeaf6013f265c7c6bb48db4 | |
| ToppCell | LPS_IL1RA_TNF-Mesenchymal_fibroblastic|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type | PTPRD PXDNL EVL SELENOP ABI3BP AFAP1 ABCA6 CCBE1 DYNC1LI1 MACF1 | 2.14e-08 | 200 | 196 | 10 | dc61016c61729f69649cfb21f6264e685ce83dea |
| ToppCell | Control_saline-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB|Control_saline / Treatment groups by lineage, cell group, cell type | ABCA1 PTPRD PXDNL EVL SELENOP ABI3BP AFAP1 ABCA6 CCBE1 MACF1 | 2.14e-08 | 200 | 196 | 10 | bd8cf33502adea320e91ca2af14e1911d88ad374 |
| ToppCell | 5'-Adult-Appendix-Epithelial-Tuft-related|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | ARHGEF38 BMX ELAPOR1 POLD1 GRIN2B OGDHL CTNNA2 CGNL1 TMEM63A | 4.47e-08 | 162 | 196 | 9 | ded08da888d8c481f0f96d1e0bfd03d617966910 |
| ToppCell | 5'-Adult-SmallIntestine-Epithelial-Tuft-related-Tuft|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 6.12e-08 | 168 | 196 | 9 | 8072d0496b7b730c4601009eaa69ec5366d26d73 | |
| ToppCell | Control-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.10e-07 | 180 | 196 | 9 | 08ae0f5d95c45feba68ad99788f7af7ff4c979af | |
| ToppCell | Control-Stromal_mesenchymal-Matrix_Fibroblast|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.10e-07 | 180 | 196 | 9 | 9b1de1b4711adbf9a423f4d2d08f3f4c78f1f8f4 | |
| ToppCell | Control-Fibroblasts-Alveolar_FB|Control / group, cell type (main and fine annotations) | 1.53e-07 | 187 | 196 | 9 | 92d468dde81125d51daf7abd4703741abe1ab91c | |
| ToppCell | nucseq-Mesenchymal-Fibroblastic-Fibroblastic_2|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 1.91e-07 | 192 | 196 | 9 | 99ce9e3c4c50cf64ebb62145f2b5420efa0db309 | |
| ToppCell | LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.00e-07 | 193 | 196 | 9 | fb28717fadd06c3840636d25409ce80c9254bd34 | |
| ToppCell | COVID-19-lung-Fibroblast|COVID-19 / Disease (COVID-19 only), tissue and cell type | 2.48e-07 | 198 | 196 | 9 | 3ec01a55ade5e1627258cc3cfebb2c3207a4cb43 | |
| ToppCell | Epithelial_cells-Basal_cells|Epithelial_cells / lung cells shred on cell class, cell subclass, sample id | 2.48e-07 | 198 | 196 | 9 | 4235005c49fc2b29ad3a0ee6b608f0109d04f775 | |
| ToppCell | nucseq-Mesenchymal|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 2.48e-07 | 198 | 196 | 9 | 8f52243ca8b9ba68a75ae411506a3a6de258eb97 | |
| ToppCell | LPS_anti-TNF-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 2.70e-07 | 200 | 196 | 9 | 9b0916d8d07ac2bf1739f7be5296bf77ffee6094 | |
| ToppCell | Control_saline-Mesenchymal_fibroblastic|Control_saline / Treatment groups by lineage, cell group, cell type | 2.70e-07 | 200 | 196 | 9 | 64ae5cf6cb4fc94cf1052abd82648f6b8e6445fe | |
| ToppCell | LPS_anti-TNF-Mesenchymal_fibroblastic-Fibroblasts|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 2.70e-07 | 200 | 196 | 9 | b79628fd1386aa9a3b0e9fa81def0bc100c3c073 | |
| ToppCell | LPS_anti-TNF-Mesenchymal_fibroblastic|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 2.70e-07 | 200 | 196 | 9 | 50ca6550998e461ef26dd670351060bd940765a8 | |
| ToppCell | Parenchyma_Control_(B.)-Stromal-TX-Fibroblasts-1|Parenchyma_Control_(B.) / Sample group, Lineage and Cell type | 2.70e-07 | 200 | 196 | 9 | aa1a35dcca3b799241eef4237f6eb94660e019f0 | |
| ToppCell | Lung_Parenchyma-Control-Mesenchymal-Mesenchymal-Fibroblasts-1|Control / Location, Disease Group, Cell group, Cell class (2021.03.09) | 2.70e-07 | 200 | 196 | 9 | a510deaada669e690329183e18df02870bd204b3 | |
| ToppCell | Parenchymal-NucSeq-Stromal|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 2.70e-07 | 200 | 196 | 9 | cf433f9b43d7db07acaf70e060f8f77c974e72f3 | |
| ToppCell | Control_saline-Mesenchymal_fibroblastic-Fibroblasts|Control_saline / Treatment groups by lineage, cell group, cell type | 2.70e-07 | 200 | 196 | 9 | a1fc74c1b27e104895910bc7cdce7ba33d30df7e | |
| ToppCell | Lung_Parenchyma-Control-Mesenchymal-Mesenchymal-Fibroblasts-1-|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 2.70e-07 | 200 | 196 | 9 | dd4228cbed8a4395166a6332e08d44d88bebe3b9 | |
| ToppCell | 5'-Adult-Appendix-Epithelial-Tuft-related-Tuft|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 4.70e-07 | 156 | 196 | 8 | 58b9520fce6e259b36c3d59e82b712f5e7729e3e | |
| ToppCell | facs-Marrow-B-cells-24m-Lymphocytic-precursor_B_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.70e-07 | 160 | 196 | 8 | c381ec6be8cf887861cc18f831a20db42f953fe1 | |
| ToppCell | facs-Marrow-B-cells-24m-Lymphocytic-pre_B_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.70e-07 | 160 | 196 | 8 | 25c8f3d2a6d14ff0ca0b965fce89d3ff22f40585 | |
| ToppCell | wk_08-11-Mesenchymal-Fibroblast-Alveolar_fibro|wk_08-11 / Celltypes from embryonic and fetal-stage human lung | 7.53e-07 | 166 | 196 | 8 | 65dafed953b01a9830b54309af75c7a561e88336 | |
| ToppCell | droplet-Lung-LUNG-30m-Endothelial-Artery_endothelial_cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.33e-06 | 179 | 196 | 8 | a09647750eba9d93c5efc1db3b555fefb5eec7b5 | |
| ToppCell | Control-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.38e-06 | 125 | 196 | 7 | b162a5bfbb8ac5e65e13578fef9de442a9e4fd8b | |
| ToppCell | Children_(3_yrs)-Mesenchymal-matrix_fibroblast_1_cell-D046|Children_(3_yrs) / Lineage, Cell type, age group and donor | 1.44e-06 | 181 | 196 | 8 | 9ede19228ba5c0668a9c06c915510b95585216ef | |
| ToppCell | droplet-Heart-HEART_(LV+RV_ONLY)-30m-Endothelial-endocardial_endothelial_cells|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.57e-06 | 183 | 196 | 8 | b0b5a41f1a40f9c946d0dc8b67eaccdd9f9b73a5 | |
| ToppCell | droplet-Kidney-nan-18m|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.63e-06 | 184 | 196 | 8 | e02859bbac36dbbd55d7ae8cb5e46b764d7c6381 | |
| ToppCell | COVID-19-Epithelial_cells-Airway_club|COVID-19 / group, cell type (main and fine annotations) | 1.70e-06 | 185 | 196 | 8 | cfe6fd73d817e173fe803bc1683c291d9bcb8608 | |
| ToppCell | COVID-19-Epithelial_cells|COVID-19 / group, cell type (main and fine annotations) | 1.92e-06 | 188 | 196 | 8 | c9cdee6f8d42ee69f5fb335f25084603c511bd29 | |
| ToppCell | LPS_only-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.99e-06 | 189 | 196 | 8 | 2a22b9fae70afb3dab8476f9c00e48a4df756410 | |
| ToppCell | LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Diff_MatrixFB|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.07e-06 | 190 | 196 | 8 | 841cd55861b43578d704418b9bc0af2e8b88323a | |
| ToppCell | PND10|World / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 2.07e-06 | 190 | 196 | 8 | d67e2814047c8df2ae4b7bc8be9539f5df6ecef2 | |
| ToppCell | LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.16e-06 | 191 | 196 | 8 | b13229bb7f3713a392271aaf5dbae3edd1b9fe5a | |
| ToppCell | LV-06._Ventricular_Cardiomyocyte_II|LV / Chamber and Cluster_Paper | 2.16e-06 | 191 | 196 | 8 | 25f3eb34f4e70761e81e84c8a5829f216108cbc6 | |
| ToppCell | droplet-Heart-nan-18m-Endothelial-endocardial_endothelial_cells|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.24e-06 | 192 | 196 | 8 | 0b9b2eaed45456d7d74ce78a64ef4a26ac2458fb | |
| ToppCell | facs-Heart-LA-3m-Endothelial-endothelial_cell_of_endocardium|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.24e-06 | 192 | 196 | 8 | 14a816ef116aa992f86edab411f043cf7d07fe04 | |
| ToppCell | facs-Heart-LA-3m-Endothelial-endocardial_cell|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.24e-06 | 192 | 196 | 8 | 847822514d747a21d5eb40e04ba9a023fd32bd65 | |
| ToppCell | LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.24e-06 | 192 | 196 | 8 | 6f4ef24dab544681304b7f8a9dc073e7edaa4cf5 | |
| ToppCell | LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.24e-06 | 192 | 196 | 8 | dcd924d6eb67d33ee9f5d3e8ab6e1d4283d6b708 | |
| ToppCell | LPS-IL1RA-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.24e-06 | 192 | 196 | 8 | deeecd26972241846b4cb998edf0c7a87ff0c4df | |
| ToppCell | Children_(3_yrs)-Mesenchymal-matrix_fibroblast_1_cell|Children_(3_yrs) / Lineage, Cell type, age group and donor | 2.33e-06 | 193 | 196 | 8 | 99525545552b371c86b18b6ea6f4897dc6e9a9ec | |
| ToppCell | Mesenchymal-matrix_fibroblast_1_cell|World / Lineage, Cell type, age group and donor | 2.33e-06 | 193 | 196 | 8 | acad568621ed677031797b8c2e34dafea798d681 | |
| ToppCell | renal_medulla_nuclei-CKD+DKD_normotensive-Epithelial-Intermediate_tubule_epithelial_cell|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 2.42e-06 | 194 | 196 | 8 | e577d9e88390b36b5a09b97fe1026089892275a3 | |
| ToppCell | LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.42e-06 | 194 | 196 | 8 | 89b706af2b25991fc2707eb24f49ba6ff3ae01f7 | |
| ToppCell | PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic-mes_immature5_(6)|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung | 2.42e-06 | 194 | 196 | 8 | b1bb0f846d2865efdd9bc8842b16b9d069785882 | |
| ToppCell | LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.42e-06 | 194 | 196 | 8 | 60622bd2f75bfe4c37f721cb12f03dab33f2f58d | |
| ToppCell | COVID-19-Fibroblasts-Alveolar_FB|COVID-19 / group, cell type (main and fine annotations) | 2.52e-06 | 195 | 196 | 8 | 603050beeb33c331d4b2e3fa46cae3f3e0e4bdc7 | |
| ToppCell | Adult-Mesenchymal-matrix_fibroblast_1_cell-D122|Adult / Lineage, Cell type, age group and donor | 2.52e-06 | 195 | 196 | 8 | aa0add081881d349099d12efca5cdee098038d4e | |
| ToppCell | 5'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2-Alveolar_fibroblasts-Alveolar_fibroblasts_L.2.1.1.0|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 2.52e-06 | 195 | 196 | 8 | df409f94f4e83be89f7a608058ee07ce3ce3a149 | |
| ToppCell | Adult-Mesenchymal-matrix_fibroblast_1_cell|Adult / Lineage, Cell type, age group and donor | 2.52e-06 | 195 | 196 | 8 | 61c9e09fc84d1012e472185d70ad0a06cee30d6e | |
| ToppCell | 5'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2-Alveolar_fibroblasts|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 2.52e-06 | 195 | 196 | 8 | 4243190ad291d56694e2155954dbaa879c9d3844 | |
| ToppCell | PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung | 2.61e-06 | 196 | 196 | 8 | 1450cb69c5bf469e97c03bf1890f6f7c54165b8a | |
| ToppCell | Children_(3_yrs)-Mesenchymal|Children_(3_yrs) / Lineage, Cell type, age group and donor | 2.61e-06 | 196 | 196 | 8 | bc94909f9b2dc08a59eef1914148b69720569c8f | |
| ToppCell | Basal_cells-Myositis-ILD_01|World / lung cells shred on cell class, cell subclass, sample id | 2.61e-06 | 196 | 196 | 8 | 3b66f3a79b3f2ebacb4ad646f179e505ab38d6f0 | |
| ToppCell | 3'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 2.61e-06 | 196 | 196 | 8 | 9737a5f006d37b549f281e1863aca558e1e4dc99 | |
| ToppCell | 5'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 2.61e-06 | 196 | 196 | 8 | 42e9828222a9663525d571633e8a454c30bfa7f8 | |
| ToppCell | 3'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2-Alveolar_fibroblasts|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 2.61e-06 | 196 | 196 | 8 | cecf82cd5e0a3835d655f5e7478578674a63ce25 | |
| ToppCell | nucseq-Mesenchymal-Fibroblastic|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 2.61e-06 | 196 | 196 | 8 | 7d8505dac15fa59935ccf592afc54b04c4c6554f | |
| ToppCell | 3'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2-Alveolar_fibroblasts-Alveolar_fibroblasts_L.2.1.1.0|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 2.71e-06 | 197 | 196 | 8 | 13896ec65ccda0b928c91d41112dc01b480036b7 | |
| ToppCell | COVID-19-Fibroblasts-Intermediate_pathological_FB|COVID-19 / group, cell type (main and fine annotations) | 2.71e-06 | 197 | 196 | 8 | f1c8936986123a3151140c374fcd62d6705c530b | |
| ToppCell | PCW_10-12-Mesenchymal-Mesenchymal_fibroblastic-mes_immature1_(0)|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung | 2.71e-06 | 197 | 196 | 8 | 11a4c417f035e554431a8f03be13b5eefa3530c0 | |
| ToppCell | Adult-Mesenchymal|Adult / Lineage, Cell type, age group and donor | 2.82e-06 | 198 | 196 | 8 | 26e55b409db2a1637c95fae7c54b0abea1ef550c | |
| ToppCell | COVID-19-lung-Fibroblast|lung / Disease (COVID-19 only), tissue and cell type | 2.82e-06 | 198 | 196 | 8 | df3de77216f5c5d6141ec44d01c56b942f611838 | |
| ToppCell | PCW_10-12-Mesenchymal-Mesenchymal_fibroblastic|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung | 2.82e-06 | 198 | 196 | 8 | 17dc055e2a289496d9c5cdbf3297bdf906dc6d22 | |
| ToppCell | Control_saline-Mesenchymal_fibroblastic-Fibroblasts-Diff_MatrixFB|Control_saline / Treatment groups by lineage, cell group, cell type | 2.92e-06 | 199 | 196 | 8 | c2c42ecf20d1924edc2f899c01dfa5fcf3c210b9 | |
| ToppCell | LPS_IL1RA-Mesenchymal_fibroblastic-Fibroblasts-Activated_MatrixFB|LPS_IL1RA / Treatment groups by lineage, cell group, cell type | 2.92e-06 | 199 | 196 | 8 | 8b86c69aaf60feff53aa782559cfece7342a23de | |
| ToppCell | Mesenchymal|World / Lineage, Cell type, age group and donor | 2.92e-06 | 199 | 196 | 8 | 4bac110c2b3609f6ee5d0e3275da0824a6240270 | |
| ToppCell | Bronchial-NucSeq-Stromal|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 3.03e-06 | 200 | 196 | 8 | 389cc775c8419d90fb77cd794376d2160a7bf44e | |
| ToppCell | Tracheal-NucSeq-Stromal-Fibroblastic|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 3.03e-06 | 200 | 196 | 8 | b4ccffdd79526c85e5273d27b668dbddcddba1ee | |
| ToppCell | Parenchymal-NucSeq-Stromal-Fibroblastic-Fibro_alveolar|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 3.03e-06 | 200 | 196 | 8 | 34f52003988ce6329d8deeee1ab875fa77e01e9d | |
| ToppCell | Biopsy_IPF-Mesenchymal-Myofibroblasts|Biopsy_IPF / Sample group, Lineage and Cell type | 3.03e-06 | 200 | 196 | 8 | c2c6f687c49ba790174b27c7b8b084af30b34c86 | |
| Drug | Theobromine [83-67-0]; Down 200; 22.2uM; MCF7; HT_HG-U133A | CDK16 KLHL24 BICD1 PRKD3 GLG1 DOCK6 UTY CBL PDE4DIP CSTA TMEM63A | 1.02e-06 | 197 | 193 | 11 | 3334_DN |
| Drug | D-pantothenoyl-L-cysteine | 2.38e-06 | 4 | 193 | 3 | CID000440217 | |
| Drug | Dasatinib | ABCA1 ORC6 NUAK1 CHAC1 KPNA2 NEMP1 SELENOP PSAT1 CIP2A SMC4 TEC TEX30 HMCN1 PRIM2 PODN OCLN | 3.45e-06 | 478 | 193 | 16 | ctd:D000069439 |
| Drug | Labetalol hydrochloride [32780-64-6]; Up 200; 11uM; PC3; HT_HG-U133A | 7.09e-06 | 196 | 193 | 10 | 4473_UP | |
| Disease | pantothenate kinase-associated neurodegeneration (implicated_via_orthology) | 1.11e-06 | 4 | 194 | 3 | DOID:3981 (implicated_via_orthology) | |
| Disease | galanin peptides measurement | 9.61e-06 | 7 | 194 | 3 | EFO_0010615 | |
| Disease | lipoprotein measurement, phospholipid measurement | 2.12e-05 | 85 | 194 | 6 | EFO_0004639, EFO_0004732 | |
| Disease | esterified cholesterol measurement | 2.30e-05 | 128 | 194 | 7 | EFO_0008589 | |
| Disease | total lipids in LDL measurement | 2.36e-05 | 52 | 194 | 5 | EFO_0022308 | |
| Disease | lipid measurement, lipoprotein measurement | 2.94e-05 | 90 | 194 | 6 | EFO_0004529, EFO_0004732 | |
| Disease | total lipids in large LDL | 3.70e-05 | 57 | 194 | 5 | EFO_0022163 | |
| Disease | cholesterol in large LDL measurement | 3.70e-05 | 57 | 194 | 5 | EFO_0021901 | |
| Disease | HENNEKAM LYMPHANGIECTASIA-LYMPHEDEMA SYNDROME 1 | 4.30e-05 | 2 | 194 | 2 | C4012050 | |
| Disease | lipoprotein measurement | 7.01e-05 | 105 | 194 | 6 | EFO_0004732 | |
| Disease | lipoprotein A measurement | 1.00e-04 | 112 | 194 | 6 | EFO_0006925 | |
| Disease | free cholesterol measurement | 1.05e-04 | 113 | 194 | 6 | EFO_0008591 | |
| Disease | total cholesterol measurement, low density lipoprotein cholesterol measurement | 1.11e-04 | 114 | 194 | 6 | EFO_0004574, EFO_0004611 | |
| Disease | Hypogonadotropic hypogonadism | 1.20e-04 | 15 | 194 | 3 | C0271623 | |
| Disease | response to statin, LDL cholesterol change measurement | 1.20e-04 | 15 | 194 | 3 | EFO_0007804, GO_0036273 | |
| Disease | Primary hypogonadism | 1.20e-04 | 15 | 194 | 3 | C0948896 | |
| Disease | Hypogonadism, Isolated Hypogonadotropic | 1.20e-04 | 15 | 194 | 3 | C3489396 | |
| Disease | angiopoietin-related protein 3 measurement | 1.28e-04 | 3 | 194 | 2 | EFO_0020148 | |
| Disease | Hennekam syndrome (is_implicated_in) | 1.28e-04 | 3 | 194 | 2 | DOID:0060366 (is_implicated_in) | |
| Disease | Hennekam lymphangiectasia-lymphedema syndrome | 1.28e-04 | 3 | 194 | 2 | C0340834 | |
| Disease | phospholipids:total lipids ratio | 1.37e-04 | 227 | 194 | 8 | EFO_0020946 | |
| Disease | very low density lipoprotein cholesterol measurement, phospholipids:total lipids ratio | 1.41e-04 | 291 | 194 | 9 | EFO_0008317, EFO_0020946 | |
| Disease | Hypogonadism | 1.47e-04 | 16 | 194 | 3 | C0020619 | |
| Disease | sleep duration, high density lipoprotein cholesterol measurement | 1.54e-04 | 121 | 194 | 6 | EFO_0004612, EFO_0005271 | |
| Disease | apolipoprotein A 1 measurement | ABCA1 ADCY5 CD163 XPO6 ANGPTL3 DOCK6 USP1 NEMP1 OR8J2 APOB LEPR ERLIN1 TMEM106B ABCA6 MACF1 CNOT1 | 1.65e-04 | 848 | 194 | 16 | EFO_0004614 |
| Disease | Astrocytosis | 1.78e-04 | 17 | 194 | 3 | C3887640 | |
| Disease | Gliosis | 1.78e-04 | 17 | 194 | 3 | C0017639 | |
| Disease | triglycerides in large LDL measurement | 1.83e-04 | 43 | 194 | 4 | EFO_0022319 | |
| Disease | cholesteryl ester measurement, low density lipoprotein cholesterol measurement | 1.91e-04 | 126 | 194 | 6 | EFO_0004611, EFO_0010351 | |
| Disease | docosahexaenoic acid measurement | 2.00e-04 | 127 | 194 | 6 | EFO_0007761 | |
| Disease | choline measurement | 2.27e-04 | 130 | 194 | 6 | EFO_0010116 | |
| Disease | Colorectal Carcinoma | ABCA1 PARP1 PTPRD SACS EVL SELENOP ZNF560 POLD1 APOB PTPRT ABCA6 GUCY2C OLFM2 EDRF1 | 2.44e-04 | 702 | 194 | 14 | C0009402 |
| Disease | cystathionine measurement | 2.51e-04 | 19 | 194 | 3 | EFO_0010474 | |
| Disease | tyrosine-protein kinase TEC measurement | 2.56e-04 | 4 | 194 | 2 | EFO_0020830 | |
| Disease | total lipids in lipoprotein particles measurement | 2.81e-04 | 48 | 194 | 4 | EFO_0022309 | |
| Disease | phospholipids in medium LDL measurement | 3.05e-04 | 49 | 194 | 4 | EFO_0022183 | |
| Disease | free cholesterol in large LDL measurement | 3.56e-04 | 51 | 194 | 4 | EFO_0022176 | |
| Disease | Attention Deficit Disorder | 3.93e-04 | 22 | 194 | 3 | C0041671 | |
| Disease | Minimal Brain Dysfunction | 3.93e-04 | 22 | 194 | 3 | C1321905 | |
| Disease | cholesteryl ester measurement, intermediate density lipoprotein measurement | 3.99e-04 | 94 | 194 | 5 | EFO_0008595, EFO_0010351 | |
| Disease | phospholipids in medium HDL measurement | 4.75e-04 | 55 | 194 | 4 | EFO_0022295 | |
| Disease | triglycerides in LDL measurement | 5.09e-04 | 56 | 194 | 4 | EFO_0022320 | |
| Disease | Attention deficit hyperactivity disorder | 5.12e-04 | 24 | 194 | 3 | C1263846 | |
| Disease | Colorectal Neoplasms | 5.22e-04 | 277 | 194 | 8 | C0009404 | |
| Disease | total lipids in medium HDL measurement | 5.82e-04 | 58 | 194 | 4 | EFO_0022310 | |
| Disease | free cholesterol in medium HDL measurement | 5.82e-04 | 58 | 194 | 4 | EFO_0022267 | |
| Disease | phosphatidylcholine measurement | 6.14e-04 | 284 | 194 | 8 | EFO_0010226 | |
| Disease | phospholipids in small LDL measurement | 6.22e-04 | 59 | 194 | 4 | EFO_0022297 | |
| Disease | Pure gonadal dysgenesis 46,XY | 6.34e-04 | 6 | 194 | 2 | cv:C2936694 | |
| Disease | interleukin-1 receptor-like 1 measurement | 6.34e-04 | 6 | 194 | 2 | EFO_0801713 | |
| Disease | Lissencephaly | 6.34e-04 | 6 | 194 | 2 | C0266463 | |
| Disease | neuroimaging measurement, brain volume measurement | 6.43e-04 | 286 | 194 | 8 | EFO_0004346, EFO_0006930 | |
| Disease | fatty acid measurement | 6.61e-04 | 436 | 194 | 10 | EFO_0005110 | |
| Disease | phospholipids in HDL measurement | 7.05e-04 | 61 | 194 | 4 | EFO_0022293 | |
| Disease | triglycerides in medium LDL measurement | 7.50e-04 | 62 | 194 | 4 | EFO_0022322 | |
| Disease | triglycerides:total lipids ratio, very low density lipoprotein cholesterol measurement | 7.53e-04 | 225 | 194 | 7 | EFO_0008317, EFO_0020947 | |
| Disease | total lipids in HDL measurement | 7.97e-04 | 63 | 194 | 4 | EFO_0022307 | |
| Disease | Semantic Dementia | 8.84e-04 | 7 | 194 | 2 | C0338462 | |
| Disease | hepatocyte growth factor receptor measurement | 8.84e-04 | 7 | 194 | 2 | EFO_0008153 | |
| Disease | Child Development Disorders, Specific | 9.01e-04 | 29 | 194 | 3 | C0085997 | |
| Disease | Child Development Deviations | 9.01e-04 | 29 | 194 | 3 | C0085996 | |
| Disease | low density lipoprotein cholesterol measurement, lipid measurement | 9.60e-04 | 114 | 194 | 5 | EFO_0004529, EFO_0004611 | |
| Disease | ceramide measurement | 9.71e-04 | 235 | 194 | 7 | EFO_0010222 | |
| Disease | Developmental Disabilities | 9.97e-04 | 30 | 194 | 3 | C0008073 | |
| Disease | common carotid intimal medial thickness | 1.00e-03 | 67 | 194 | 4 | EFO_0004860 | |
| Disease | dehydroepiandrosterone sulphate measurement | 1.06e-03 | 68 | 194 | 4 | EFO_0007001 | |
| Disease | C-reactive protein measurement | USP34 TDRD15 ABCA1 CCDC168 IL18RAP ADCY5 MAP3K1 HFM1 KIAA2012 IP6K2 APOB CBL LEPR GLMN ABCA6 DNAJC5 MACF1 IL1RL1 | 1.07e-03 | 1206 | 194 | 18 | EFO_0004458 |
| Disease | very low density lipoprotein cholesterol measurement, free cholesterol:total lipids ratio | 1.07e-03 | 239 | 194 | 7 | EFO_0008317, EFO_0020945 | |
| Disease | alkaline phosphatase measurement | USP34 TDRD15 SAMD9 SLC26A4 CHD3 ADCY5 XPO6 HFM1 B4GALNT3 APOB LEPR TMEM106B ABCA6 SLF2 MACF1 CNOT1 | 1.16e-03 | 1015 | 194 | 16 | EFO_0004533 |
| Disease | esterified cholesterol measurement, intermediate density lipoprotein measurement | 1.17e-03 | 8 | 194 | 2 | EFO_0008589, EFO_0008595 | |
| Disease | holoprosencephaly (is_implicated_in) | 1.17e-03 | 8 | 194 | 2 | DOID:4621 (is_implicated_in) | |
| Disease | Fanconi anemia (implicated_via_orthology) | 1.17e-03 | 8 | 194 | 2 | DOID:13636 (implicated_via_orthology) | |
| Disease | pantothenate measurement | 1.17e-03 | 8 | 194 | 2 | EFO_0021034 | |
| Disease | Hantavirus hemorrhagic fever with renal syndrome (is_marker_for) | 1.17e-03 | 8 | 194 | 2 | DOID:11266 (is_marker_for) | |
| Disease | circulating alpha-Klotho measurement | 1.17e-03 | 8 | 194 | 2 | EFO_0020102 | |
| Disease | Primary Progressive Nonfluent Aphasia | 1.17e-03 | 8 | 194 | 2 | C0751706 | |
| Disease | free cholesterol measurement, high density lipoprotein cholesterol measurement | 1.20e-03 | 315 | 194 | 8 | EFO_0004612, EFO_0008591 | |
| Disease | feeling tense measurement | 1.32e-03 | 33 | 194 | 3 | EFO_0009596 | |
| Disease | myeloid white cell count | USP34 SLC38A9 TRPC6 NAIP PSMD3 ITGA4 ADCY5 XPO6 GLG1 HFM1 SELENOP LRRK1 LEPR GLMN TREML2 | 1.41e-03 | 937 | 194 | 15 | EFO_0007988 |
| Disease | pancreatitis (implicated_via_orthology) | 1.50e-03 | 9 | 194 | 2 | DOID:4989 (implicated_via_orthology) | |
| Disease | Pancreatitis, Chronic | 1.50e-03 | 9 | 194 | 2 | C0149521 | |
| Disease | low tension glaucoma | 1.50e-03 | 9 | 194 | 2 | EFO_1001022 | |
| Disease | Behavioral variant of frontotemporal dementia | 1.50e-03 | 9 | 194 | 2 | C4011788 | |
| Disease | rectum cancer (is_implicated_in) | 1.50e-03 | 9 | 194 | 2 | DOID:1993 (is_implicated_in) | |
| Disease | free cholesterol in small HDL measurement | 1.57e-03 | 35 | 194 | 3 | EFO_0022270 | |
| Disease | Cardiomyopathies | 1.72e-03 | 130 | 194 | 5 | C0878544 | |
| Disease | Alzheimer's disease (is_implicated_in) | 1.84e-03 | 132 | 194 | 5 | DOID:10652 (is_implicated_in) | |
| Disease | free cholesterol to total lipids in large VLDL percentage | 1.84e-03 | 37 | 194 | 3 | EFO_0022281 | |
| Disease | protein intake measurement | 1.87e-03 | 10 | 194 | 2 | EFO_0010810 | |
| Disease | very low density lipoprotein cholesterol measurement, cholesteryl esters:total lipids ratio | 1.89e-03 | 264 | 194 | 7 | EFO_0008317, EFO_0020944 | |
| Disease | omega-6 polyunsaturated fatty acid measurement | 1.99e-03 | 197 | 194 | 6 | EFO_0005680 | |
| Disease | Degenerative Diseases, Central Nervous System | 2.15e-03 | 39 | 194 | 3 | C0270715 | |
| Disease | Neurodegenerative Disorders | 2.15e-03 | 39 | 194 | 3 | C0524851 | |
| Disease | Degenerative Diseases, Spinal Cord | 2.15e-03 | 39 | 194 | 3 | C0751733 | |
| Disease | Hypercholesterolemia | 2.15e-03 | 39 | 194 | 3 | C0020443 | |
| Disease | free cholesterol measurement, low density lipoprotein cholesterol measurement | 2.16e-03 | 137 | 194 | 5 | EFO_0004611, EFO_0008591 | |
| Disease | interleukin 1 receptor-like 1 measurement | 2.27e-03 | 11 | 194 | 2 | EFO_0008168 | |
| Disease | 46,XY partial gonadal dysgenesis | 2.27e-03 | 11 | 194 | 2 | C4510744 | |
| Disease | serum ST2 measurement | 2.27e-03 | 11 | 194 | 2 | EFO_0005416 | |
| Disease | cholesterol in very small VLDL measurement | 2.31e-03 | 40 | 194 | 3 | EFO_0022231 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| TYYLSVNRNKKSIAV | 101 | Q9HAC7 | |
| DRSIQKVYKTYNGTN | 116 | O60637 | |
| KSSEEITQYIQSYKG | 231 | Q13075 | |
| KTLRTLQYDGFKTVY | 31 | B9A014 | |
| QESASKEAYYLGKIL | 96 | Q96G01 | |
| IATALEYVYKGQLQS | 136 | P78537 | |
| SKLRSYQYVKLSGNF | 841 | Q6L9W6 | |
| SAIYSKYANGIEIQL | 171 | Q5T601 | |
| TSLAQYDSNSKKIYG | 211 | P51813 | |
| AVVKRTGSNAAQYKY | 541 | Q8N556 | |
| TKFNYGSIIKAIYQA | 346 | P15085 | |
| KLLSTYSAEELYQAK | 576 | Q9NXL2 | |
| EYLELKKYQAIASNS | 281 | O75477 | |
| SNYTTVKIKNGKVYF | 4266 | Q6V0I7 | |
| SDYLVKTYVQIIAKS | 1506 | O95477 | |
| SYNGAIIVSGKQKDY | 946 | Q8N139 | |
| NLLSSNKYTEKQIGY | 81 | O95782 | |
| NKYTEKQIGYLFISV | 86 | O95782 | |
| FYKEYLSVIIAKNGS | 1061 | Q9C0A0 | |
| KKKYVTLSSNGFLLY | 696 | Q99490 | |
| GLEKIYSIVKQSNYV | 316 | Q9Y5C1 | |
| ITKATLNYLNGDYEV | 606 | O95622 | |
| YTNTTNKEEKIQLAY | 846 | Q6Q4G3 | |
| VIKYCTTYQSKGQTL | 486 | P98194 | |
| KSTSKYIYQTLFLNG | 91 | Q96IK5 | |
| GSLFYNKYQSNVVVK | 276 | O95897 | |
| VNDTKGVAISTYAKY | 836 | Q9C0H5 | |
| ASYKKGTLEYLQLNT | 1051 | P25092 | |
| YNRLKQVKGSADYKS | 481 | Q16625 | |
| DIVKGTNSYYKLQLL | 561 | P09874 | |
| QTLKYTIKYIGELTD | 166 | A6NI15 | |
| LTESPKYIQKQISYN | 231 | Q8NC51 | |
| AKITSDYQATQKITY | 71 | P32926 | |
| ISSKKLVDYILGTYQ | 396 | P32926 | |
| ANYLTKIYGLTFGQK | 176 | Q7Z5L7 | |
| KSIYYITGESKEQVA | 481 | P08238 | |
| DSTYQYIKGSADIKS | 156 | P49441 | |
| LYRTYQSKDQTLGDK | 391 | O95256 | |
| TGKNSCYENISELKY | 686 | Q9P2G4 | |
| YQASTSELYGKVQEI | 151 | O60547 | |
| IYGNQDTSSQLKKFY | 476 | P19823 | |
| SEVLYYTVEKKGNIS | 156 | Q9UHH9 | |
| SVYATSLQSDVNYKK | 1091 | Q86VF7 | |
| TATEDQKIYIYTLKG | 1596 | Q38SD2 | |
| QKAILSKFLYYSING | 201 | Q3B7T1 | |
| QKSIYYITGESKEQV | 256 | Q58FF8 | |
| SKGKQSYTYIIEENT | 531 | Q6UXG2 | |
| LQYGAALIYTSVKEN | 276 | Q9Y6G9 | |
| NSVYGKVLDQYKSLI | 5026 | Q5CZC0 | |
| NYIYKTLGVNKQTEN | 636 | Q5T0W9 | |
| TGKVYYDLVKERSSQ | 891 | Q9ULD0 | |
| ESTSKNYYKLVIAGA | 391 | Q9Y5G3 | |
| SSSKNYYKLVTDGAL | 396 | Q9Y5G2 | |
| KEKLNDTYVNVGLYS | 121 | O14524 | |
| GKTYLANKLAEYVIT | 2061 | Q8IVL0 | |
| INYSIVKGLKYNQAT | 61 | Q9UI08 | |
| LYASKESYNEKTQQT | 286 | Q0VF49 | |
| TLFQNESGSKYYKEI | 446 | O94806 | |
| NNDKKSIYYLGVTSI | 1071 | P48357 | |
| SLLLQIVYGNYESKK | 556 | O00522 | |
| ANKRKYTSSYEALKG | 316 | A8MYU2 | |
| SKQYQNILKSGTLYR | 356 | Q6ZWE6 | |
| KSLTYYTNLQVKTGQ | 281 | O94886 | |
| ILTDATKRNIYDKYG | 66 | Q9H3Z4 | |
| YQITNKSTEYKVIGH | 476 | O00222 | |
| AKVEAIQSGSNYAYL | 1006 | P29375 | |
| YGLSTVYLNKLKTVD | 1146 | Q9UPN3 | |
| TAGYAKRKVQLTVYV | 1056 | Q96RW7 | |
| ETDTIYYKNISGFKT | 1326 | Q9UMZ3 | |
| ETNGVITLYEINYKA | 511 | O14522 | |
| KSIRKYLTSNVAYGS | 46 | Q9H999 | |
| LTYASQKYKNHIGTE | 121 | A2PYH4 | |
| NESVYKASLSLIEKY | 481 | P52292 | |
| LNISTKEYAYLKGTV | 371 | P51843 | |
| KSIRKYLTSNVAYGS | 246 | Q9BZ23 | |
| ILAVYSKDNYKRVTG | 396 | Q9BZ23 | |
| LVTKKTISYYGCAAQ | 86 | Q8NGG1 | |
| VSYVKGTEQYQSKLE | 61 | P49643 | |
| VTQESQKKRSAQYSY | 1311 | A1KZ92 | |
| SYGTKILYQNTEALQ | 26 | Q16698 | |
| LIAQDYKVSYSLAKS | 361 | Q92896 | |
| KNTASLKYENYELTL | 1556 | P04114 | |
| YELTLKSDTNGKYKN | 1566 | P04114 | |
| RYSGKTEYQTTKTNK | 346 | Q9HCM4 | |
| RTGYANVTIYKKQSD | 96 | Q01638 | |
| ASDGKVTRTAYNLYK | 876 | Q659A1 | |
| LQYVYTGKVKITTEN | 121 | Q6TFL4 | |
| KYKYIVLNSQASQAG | 196 | Q8N143 | |
| NYKSGLVQKSLYIQA | 661 | A2AJT9 | |
| GSYILNSYKDEKNSK | 201 | Q5JSL3 | |
| SKLDSQKAYIQITYV | 1811 | Q96HP0 | |
| ASTKYQKVYGTAAVN | 886 | P26232 | |
| ALIGETVNNYRSTKY | 386 | Q03188 | |
| KQILYNYLKEGSTDN | 556 | Q0VF96 | |
| YATVYKGKSKLTDNL | 176 | Q00536 | |
| TVTKYSGSLLLQKKY | 91 | Q7Z3S7 | |
| GKTIQTIVFLYSLYK | 766 | Q12873 | |
| AGIYNETTKQKLGIY | 2261 | P15924 | |
| KYITGDKVLASNTYL | 231 | Q6UXH8 | |
| AYQVQGEQVSKALKY | 96 | Q9BUX1 | |
| AGNSYIKYRLSENSK | 3841 | Q8TDW7 | |
| KDVQTYYGQVLKRSA | 11 | Q9HBK9 | |
| LSYVGTLQKVYFKSN | 66 | Q9Y5Q5 | |
| TNETYGKLEAVQYKT | 31 | P01040 | |
| KQNQVKFGSYLGYSV | 241 | P13612 | |
| NYYKTTSSEINAIVG | 696 | Q8N7U6 | |
| YTSVYDKNNLLTNKT | 261 | Q9Y2T3 | |
| VANAKGLQYYSTLLD | 166 | Q86Z14 | |
| VESAYEVIKLKGYTN | 236 | P07195 | |
| SKLYISQLQKGKYSI | 306 | Q5PSV4 | |
| SQGYSYQDIQKALVI | 866 | P22681 | |
| YKGYVNNTTVAVKKL | 201 | Q9NWZ3 | |
| ASNLLKRYAEKYSGV | 56 | A6NMB9 | |
| DTGKLKYTLSYLNDI | 4606 | Q8NDH2 | |
| CGSALKTSYQVYSKI | 416 | Q86VB7 | |
| GKTVQTAVFLYSLYK | 756 | Q14839 | |
| YTKTVLNYLQSSGKQ | 586 | Q9NZJ4 | |
| KLQSYTEGYGKNTSL | 106 | Q8NBW4 | |
| TKQLVESKYTVENGY | 731 | P28340 | |
| TLEYGNYTALAKVQI | 746 | Q8TDX9 | |
| YLIGKDITNKLYSLN | 251 | Q8NE79 | |
| TTYTGSYRKKQLDKS | 46 | C9J302 | |
| TAKYNACILEYKQSG | 81 | Q16531 | |
| KYGIKVSTSDQYDVL | 116 | O14713 | |
| RNSTYEKLDLKVYGT | 341 | Q8N4N8 | |
| EKQNGIITEYSIKYT | 636 | P23468 | |
| KSIRKYLTSNTAYGK | 271 | Q8TE04 | |
| ILAVYSKDNYKRVTG | 421 | Q8TE04 | |
| SKYGAFKESVVINYT | 1336 | Q13233 | |
| KFYQLSATGQKLYVR | 406 | Q9Y2M0 | |
| YINKLDSQGKYTLFR | 391 | Q92990 | |
| SSNVSYKYSKVNKEE | 2346 | P11717 | |
| AQKGAYIELTLQTYQ | 336 | P82650 | |
| IGVKSAYVSYDVQKR | 126 | Q9NUM4 | |
| TKESYAIQYLQKSLE | 261 | O14607 | |
| AYAVIQVGKEKYATS | 41 | Q6WKZ4 | |
| TLSVQCSYKGYKNRV | 36 | Q5T2D2 | |
| ISFTVKYTYQGLKQE | 431 | P52630 | |
| KYTYQGLKQELKTDT | 436 | P52630 | |
| KSVSFYTRKDGQLIY | 101 | P49768 | |
| IYLNAKVKGYVSNIS | 1291 | B5MCY1 | |
| SNYVTGKKSNNLDQY | 231 | P42680 | |
| TGKIKTALIENAIYY | 141 | Q68DH5 | |
| SFRGQSVKYVYKLTI | 126 | Q92546 | |
| KFYVSLGEASYTQTK | 191 | Q8NE09 | |
| KTNRTLYLFGVTKYI | 196 | Q00889 | |
| NSYISDTLGQVYKSK | 1116 | Q5K651 | |
| SKTNRTLYLFGVTKY | 196 | Q00887 | |
| SVLEYKVQAGNSSLY | 226 | Q9Y617 | |
| VKTYLNENGYAVSGK | 626 | Q9H2Y9 | |
| NNLTTGKIYQYVINK | 86 | P17812 | |
| VNVQKISNLLSDYGY | 1006 | P30876 | |
| GILKKTQQRESGYYS | 466 | O60285 | |
| AYLIKLSGLNKETYQ | 66 | Q9Y5N6 | |
| ETKDTIQNGNYILYT | 836 | P14410 | |
| LSLASKYLAKGTNIY | 136 | Q8IX21 | |
| QSVQQVYYSIGALAK | 416 | P13533 | |
| LKKEGYSNISYIVVN | 76 | P49908 | |
| KTKLEAQAYTAYLSG | 181 | Q9UHB9 | |
| KNIYLNSGLTSTKNY | 376 | P78536 | |
| KLTYNVKIFYSGANI | 126 | Q8TCG1 | |
| FDLKGIYTRLNTYTK | 261 | Q7L1S5 | |
| SQISYLVDNLTKKNY | 11 | A5YKK6 | |
| SSESKGKVQLLYYVN | 451 | P48736 | |
| TDDYLSNLIKAKSYI | 216 | Q9BXT8 | |
| SEGKYSKVYALRTQK | 186 | Q96PP4 | |
| NLYKDNNITTGKIYQ | 81 | Q9NRF8 | |
| SSDKITTGYKYKRLQ | 321 | Q96T68 | |
| YSLYDQAEKLVSKSV | 261 | O43242 | |
| NVSTKNYNGVLSIIY | 241 | O43511 | |
| TLGIALKFYNYSITK | 406 | Q7RTY8 | |
| SGETEKLYQLLTQYK | 96 | Q96DB5 | |
| TIKKSGASYAYILEA | 96 | Q9UM01 | |
| SGRKSVFQKLYDLYI | 31 | Q8NEM7 | |
| RLIGIYKTYNITKSV | 1261 | Q9NTJ3 | |
| YNSYKTQAGSSKTEK | 601 | Q96N46 | |
| KAYKSVLNYLKTSGE | 76 | Q5JUR7 | |
| GRYLTQETNKVETYK | 101 | P12272 | |
| CYKYGQTLDLSKNSI | 491 | Q9NYK1 | |
| DVKTQSISYLAYQGA | 1426 | Q4KWH8 | |
| LGTTYKRDLNSYKVQ | 46 | Q658L1 | |
| AKGFSIYNLYSAKQI | 121 | Q6P2C0 | |
| LTNNDLYRIFSKYGK | 21 | Q8TBF4 | |
| VQLKNYGKFLEEYTS | 26 | Q2M389 | |
| LTTTQNKIFQYDKYV | 146 | A6NK75 | |
| ATNKKGQETYYTAAQ | 286 | Q86VQ6 | |
| YNYSIIGTFTVKLKV | 196 | Q8N3G9 | |
| IKKLTGSTERYDQNY | 116 | Q7L2R6 | |
| SSQVKEYLQSLSYKD | 256 | Q8N6G2 | |
| DLTKVTLGDNVKYYN | 566 | Q9Y210 | |
| INSYYINGKTGLEKE | 1121 | Q70CQ2 | |
| VKVTLYGSQIKLYNI | 591 | Q96QU8 | |
| KIYLSDSLTGKFYNI | 981 | Q7Z7G0 | |
| TLELQIAKDKNYGSY | 316 | Q12836 | |
| NKISYVVQSLKEYEG | 731 | O94782 | |
| ENYKNLSSVGYQLFK | 141 | Q96MR9 | |
| QYAKDLLSLYNKTST | 246 | Q96MR9 | |
| YIITSKGKGNANLEY | 131 | Q7Z7D3 | |
| YKAQGSSQENYFVIK | 191 | B1ANS9 | |
| IYSSEAIKSYQGKSL | 106 | Q9UM54 | |
| YLKVSDLQQGKTYVF | 871 | P54296 | |
| SELQIYEALYGNSKK | 2011 | Q5VU43 | |
| TGTEKLIETYFSKNY | 41 | P60201 | |
| SVKFTYDLYLVTNGK | 471 | Q13224 |